Key result
Dual-antiplatelet therapy with high-intensity statin for 90 days was associated with a lower rate of early neurological deterioration (2.4% vs 7.7%, HR 0.66) compared to single-antiplatelet therapy with high-intensity statin for 60 days.
Why the study?
The study was conducted to evaluate the efficacy and safety of two treatment regimens combining antiplatelet therapy and high-intensity statins for stroke or high-risk TIA of atherosclerotic origin.
Does DAPT followed by SAPT with 90-day high-intensity statin reduce early neurological deterioration and recurrent stroke compared to SAPT with 60-day high-intensity statin in patients with stroke or high-risk TIA of atherosclerotic origin?
Population
160 patients with atherosclerotic stroke (NIHSS 1–10) without reperfusion or high-risk TIA (ABCD 2 ≥4)
Comparison
DAPT (days 1–21) then SAPT (days 22–90) plus HIS for 90 days vs SAPT plus HIS for 60 days
Design
Prospective observational cohort study
Follow-up
Three months
Authors
Loading...
May support prolonged DAPT in stroke; leaves open need for RCTs before practice change.
Cohort (n=160)
No
Does DAPT followed by SAPT with 90-day high-intensity statin reduce early neurological deterioration and recurrent stroke compared to SAPT with 60-day high-intensity statin in patients with stroke or high-risk TIA of atherosclerotic origin?
Hazard Ratio: 0.66 (95% CI 0.42–0.91)
Absolute Event Rate: 2.4% vs 7.7%
p-value: p=0.08
In patients with stroke or high-risk TIA of atherosclerotic origin, DAPT followed by SAPT with 90-day high-intensity statin therapy improves neurofunctional recovery and shows a trend toward reducing early neurological deterioration and recurrent stroke compared to SAPT with 60-day high-intensity statin.
Suryawanshi et al. (2025) conducted a cohort in Stroke or high-risk transient ischemic attack (TIA) of atherosclerotic origin (n=160). Dual-antiplatelet therapy (1-21 days) followed by single-antiplatelet therapy (22-90 days) with high-intensity statin for 90 days vs. Single-antiplatelet therapy for 90 days with high-intensity statin for 60 days was evaluated on Early neurological deterioration (END) (HR 0.66, 95% CI 0.42-0.91, p=0.08). Dual-antiplatelet therapy with high-intensity statin for 90 days was associated with a lower rate of early neurological deterioration (2.4% vs 7.7%, HR 0.66) compared to single-antiplatelet therapy with high-intensity statin for 60 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: